Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Hilf N, et al. Among authors: gouttefangeas c. Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z. Nature. 2019. PMID: 30733620
Problem solving for tumor immunotherapy.
Gouttefangeas C, Rammensee HG. Gouttefangeas C, et al. Nat Biotechnol. 2000 May;18(5):491-2. doi: 10.1038/75343. Nat Biotechnol. 2000. PMID: 10802611 No abstract available.
Towards patient-specific tumor antigen selection for vaccination.
Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanović S. Rammensee HG, et al. Among authors: gouttefangeas c. Immunol Rev. 2002 Oct;188:164-76. doi: 10.1034/j.1600-065x.2002.18815.x. Immunol Rev. 2002. PMID: 12445290 Review.
CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors.
Dittmann J, Keller-Matschke K, Weinschenk T, Kratt T, Heck T, Becker HD, Stevanović S, Rammensee HG, Gouttefangeas C. Dittmann J, et al. Among authors: gouttefangeas c. Cancer Immunol Immunother. 2005 Aug;54(8):750-8. doi: 10.1007/s00262-004-0640-7. Epub 2004 Dec 22. Cancer Immunol Immunother. 2005. PMID: 15614528 Free PMC article.
114 results